EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis. (Q48565199)

12 February 2018

title

EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis. (English)

1 reference

12 February 2018

0 references

0 references

7

F Fazekas

1 reference

12 February 2018

6

N De Stefano

1 reference

12 February 2018

M Filippi

1

1 reference

12 February 2018

M A Rocca

2

1 reference

12 February 2018

D L Arnold

3

1 reference

12 February 2018

R Bakshi

4

1 reference

12 February 2018

F Barkhof

5

1 reference

12 February 2018

E Frohman

8

1 reference

12 February 2018

J S Wolinsky

9

1 reference

12 February 2018

publication date

1 April 2006

1 reference

12 February 2018

European Journal of Neurology

published in

1 reference

12 February 2018

volume

13

1 reference

12 February 2018

page(s)

313-325

1 reference

12 February 2018

issue

4

1 reference

12 February 2018

The use of magnetic resonance imaging in the diagnosis and long-term management of multiple sclerosis

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Magnetic resonance techniques to monitor disease evolution and treatment trial outcomes in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Characteristics of chronic MS lesions in the cerebrum, brainstem, spinal cord, and optic nerve on T1-weighted MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Management of acute optic neuritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Magnetic resonance imaging of the optic nerve in optic neuritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Optic neuritis: MR imaging with combined fat- and water-suppression techniques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Serial magnetization transfer imaging in acute optic neuritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Magnetic resonance imaging of the head in the diagnosis of multiple sclerosis: a prospective 2-year follow-up with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Assessment of MRI criteria for a diagnosis of MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Measurement of spinal cord atrophy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Measurement of spinal cord area in clinically isolated syndromes suggestive of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Normal-appearing brain tissue MTR histograms in clinically isolated syndromes suggestive of MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Evidence for axonal pathology and adaptive cortical reorganization in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Progression of cerebral white matter lesions: 6-year results of the Austrian Stroke Prevention Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Diagnostic criteria for primary progressive multiple sclerosis: a position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

The role of magnetic resonance techniques in understanding and managing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

MRI techniques to monitor MS evolution: the present and the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

From enhancing lesions to brain atrophy in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: relationship to course, gender, and age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

A controlled trial of natalizumab for relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Current approved options for treating patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Oral simvastatin treatment in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Primary and transitional progressive MS: a clinical and MRI cross-sectional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Development of hypointense lesions on T1-weighted spin-echo magnetic resonance images in multiple sclerosis: relation to inflammatory activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Central nervous system atrophy and clinical status in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Eight-year follow-up study of brain atrophy in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Brain atrophy in clinically early relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Evidence of early cortical atrophy in MS: relevance to white matter changes and disability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Whole brain volume changes in patients with progressive MS treated with cladribine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Measurement of whole-brain atrophy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Magnetization transfer ratio in new MS lesions before and during therapy with IFNbeta-1a

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Guidelines for using quantitative magnetization transfer magnetic resonance imaging for monitoring treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Total brain N-acetylaspartate: a new measure of disease load in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Multicentre proton magnetic resonance spectroscopy imaging of primary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

An MT MRI study of the cervical cord in clinically isolated syndromes suggestive of MS

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

Correlations between clinical and MRI involvement in multiple sclerosis: assessment using T1, T2 and MT histograms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

A Longitudinal Magnetic Resonance Imaging Study of the Cervical Cord in Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

European Study on Intravenous Immunoglobulin in Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01543.X

10.1111/J.1468-1331.2006.01543.X

21 January 2018

Identifiers

DOI

1 reference

12 February 2018

PubMed ID

16643308

1 reference

12 February 2018